| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2001;104:1923.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Laboratory of Clinical Epidemiology (L.F.), INRCA Geriatric Department, Florence, Italy; Department of Public Health Sciences (C.D.F., J.G.C.), Sticht Center on Aging, Section on Gerontology and Geriatrics (B.W.J.H.P., M.D.B., J.D.W., M.P.), and Department of Internal Medicine (W.B.A.), Wake Forest University, Winston Salem, NC; Department of Critical Care Medicine and Surgery, Section of Gerontology and Geriatric Medicine (L.F., M.D.B.), Azienda Ospedaliera Careggi, Florence, Italy; and Epidemiology, Demography and Biometry Program (J.M.G.), National Institute on Aging, National Institutes of Health, Bethesda, Md.
Correspondence to Luigi Ferrucci, MD, PhD, Laboratory of Clinical Epidemiology, INRCA Geriatric Department, Viale Michelangiolo, 41, 50125 Florence, Italy. E-mail ferrucci{at}dada.it
Background Although present guidelines suggest that treatment of hypertension is more effective in patients with multiple risk factors and higher risk of cardiovascular events, this hypothesis was never verified in older patients with systolic hypertension.
Methods and Results Using data from the Systolic Hypertension in the Elderly Program, we calculated the global cardiovascular risk score according to the American Heart Association Multiple Risk Factor Assessment Equation in 4,189 participants free of cardiovascular disease (CVD) and in 264 participants with CVD at baseline. In the placebo group, rates of cardiovascular events over 4.5 years were progressively higher according to higher quartiles of CVD risk. The protection conferred by treatment was similar across quartiles of risk. However, the numbers needed to treat (NNTs) to prevent one cardiovascular event were progressively smaller according to higher cardiovascular risk quartiles. In participants with baseline CVD, the NNTs to prevent one cardiovascular event were similar to those estimated for CVD-free participants in the highest-risk quartile.
Conclusions Treatment of systolic hypertension is most effective in older patients who, because of additional risk factors or prevalent CVD, are at higher risk of developing a cardiovascular event. These patients are prime candidates for antihypertensive treatment.
Key Words: hypertension aging risk factors cardiovascular diseases trials
This article has been cited by other articles:
![]() |
S. M. Grundy Metabolic Syndrome: Connecting and Reconciling Cardiovascular and Diabetes Worlds J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1093 - 1100. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Rodriguez-Manas, M. Castro, and J. Manzarbeitia Review: Cardiovascular risk and diabetes in old people The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1): 7 - 11. [Abstract] [PDF] |
||||
![]() |
OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02) Evid. Based Nurs., January 1, 2003; 6(1): e1 - 1. [Full Text] [PDF] |
||||
![]() |
L. R. Krakoff, T. Pickering, R. Phillips, A. M. Grandi, A. Venco, and M. Moser ABPM Is Valuable for the Management of Hypertension Arch Intern Med, July 8, 2002; 162(13): 1528 - 1530. [Full Text] [PDF] |
||||
![]() |
J. Gray Treating isolated systolic hypertension prevented major cardiovascular events across strata of risk in older patients Evid. Based Med., July 1, 2002; 7(4): 109 - 109. [Full Text] [PDF] |
||||
![]() |
K. Rees, S. Ebrahim, J. L. Tang, W. Tam, and B. Leckridge Secondary prevention of coronary heart disease BMJ, March 9, 2002; 324(7337): 611 - 611. [Full Text] |
||||
![]() |
H. L Elliott and G. T McInnes Special management needs of the elderly hypertensive patient Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1_suppl): S25 - S31. [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |